Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease

Xavier M. Keutgen, Pascal Hammel, Peter L. Choyke, Steven K. Libutti, Eric Jonasch, Electron Kebebew

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

von Hippel–Lindau (VHL) disease is a heritable cancer-predisposition syndrome with multiorgan involvement. Pancreatic lesions are detected in approximately two-thirds of patients with VHL disease at some point during their lifetime. In these patients, cystic pancreatic lesions are almost exclusively benign and, unless symptomatic, do not require surgical or endoscopic intervention; however, solid pancreatic lesions can often be recognized through imaging screens, and are commonly found to be nonfunctioning pancreatic neuroendocrine tumours (pNETs) with malignant potential. The natural history of these VHL-associated pNETs is variable, and lacks clinical or imaging features that predict disease progression or metastatic potential, and generally needs to be managed more conservatively than their sporadic counterparts. Treatment options for such lesions, which range from active surveillance to surgical intervention, can nevertheless be associated with considerable morbidity and even mortality. Of note, although several guidelines have been established for the management of tumours associated with VHL syndrome, none of these have specifically focused on pancreatic lesions. Thus, we aim to characterize the types of pancreatic lesions associated with VHL disease and their natural history, to identify particular lesions that necessitate treatment, and to define what forms of treatment should be undertaken.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - Mar 31 2016

Fingerprint

Neuroendocrine Tumors
Natural History
Disease Progression
Neoplasms
Therapeutics
Guidelines
Morbidity
Mortality

ASJC Scopus subject areas

  • Oncology

Cite this

Keutgen, X. M., Hammel, P., Choyke, P. L., Libutti, S. K., Jonasch, E., & Kebebew, E. (Accepted/In press). Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2016.37

Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease. / Keutgen, Xavier M.; Hammel, Pascal; Choyke, Peter L.; Libutti, Steven K.; Jonasch, Eric; Kebebew, Electron.

In: Nature Reviews Clinical Oncology, 31.03.2016.

Research output: Contribution to journalArticle

Keutgen, Xavier M. ; Hammel, Pascal ; Choyke, Peter L. ; Libutti, Steven K. ; Jonasch, Eric ; Kebebew, Electron. / Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease. In: Nature Reviews Clinical Oncology. 2016.
@article{0691e6238a4940f787aeb0fc982a4db8,
title = "Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease",
abstract = "von Hippel–Lindau (VHL) disease is a heritable cancer-predisposition syndrome with multiorgan involvement. Pancreatic lesions are detected in approximately two-thirds of patients with VHL disease at some point during their lifetime. In these patients, cystic pancreatic lesions are almost exclusively benign and, unless symptomatic, do not require surgical or endoscopic intervention; however, solid pancreatic lesions can often be recognized through imaging screens, and are commonly found to be nonfunctioning pancreatic neuroendocrine tumours (pNETs) with malignant potential. The natural history of these VHL-associated pNETs is variable, and lacks clinical or imaging features that predict disease progression or metastatic potential, and generally needs to be managed more conservatively than their sporadic counterparts. Treatment options for such lesions, which range from active surveillance to surgical intervention, can nevertheless be associated with considerable morbidity and even mortality. Of note, although several guidelines have been established for the management of tumours associated with VHL syndrome, none of these have specifically focused on pancreatic lesions. Thus, we aim to characterize the types of pancreatic lesions associated with VHL disease and their natural history, to identify particular lesions that necessitate treatment, and to define what forms of treatment should be undertaken.",
author = "Keutgen, {Xavier M.} and Pascal Hammel and Choyke, {Peter L.} and Libutti, {Steven K.} and Eric Jonasch and Electron Kebebew",
year = "2016",
month = "3",
day = "31",
doi = "10.1038/nrclinonc.2016.37",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease

AU - Keutgen, Xavier M.

AU - Hammel, Pascal

AU - Choyke, Peter L.

AU - Libutti, Steven K.

AU - Jonasch, Eric

AU - Kebebew, Electron

PY - 2016/3/31

Y1 - 2016/3/31

N2 - von Hippel–Lindau (VHL) disease is a heritable cancer-predisposition syndrome with multiorgan involvement. Pancreatic lesions are detected in approximately two-thirds of patients with VHL disease at some point during their lifetime. In these patients, cystic pancreatic lesions are almost exclusively benign and, unless symptomatic, do not require surgical or endoscopic intervention; however, solid pancreatic lesions can often be recognized through imaging screens, and are commonly found to be nonfunctioning pancreatic neuroendocrine tumours (pNETs) with malignant potential. The natural history of these VHL-associated pNETs is variable, and lacks clinical or imaging features that predict disease progression or metastatic potential, and generally needs to be managed more conservatively than their sporadic counterparts. Treatment options for such lesions, which range from active surveillance to surgical intervention, can nevertheless be associated with considerable morbidity and even mortality. Of note, although several guidelines have been established for the management of tumours associated with VHL syndrome, none of these have specifically focused on pancreatic lesions. Thus, we aim to characterize the types of pancreatic lesions associated with VHL disease and their natural history, to identify particular lesions that necessitate treatment, and to define what forms of treatment should be undertaken.

AB - von Hippel–Lindau (VHL) disease is a heritable cancer-predisposition syndrome with multiorgan involvement. Pancreatic lesions are detected in approximately two-thirds of patients with VHL disease at some point during their lifetime. In these patients, cystic pancreatic lesions are almost exclusively benign and, unless symptomatic, do not require surgical or endoscopic intervention; however, solid pancreatic lesions can often be recognized through imaging screens, and are commonly found to be nonfunctioning pancreatic neuroendocrine tumours (pNETs) with malignant potential. The natural history of these VHL-associated pNETs is variable, and lacks clinical or imaging features that predict disease progression or metastatic potential, and generally needs to be managed more conservatively than their sporadic counterparts. Treatment options for such lesions, which range from active surveillance to surgical intervention, can nevertheless be associated with considerable morbidity and even mortality. Of note, although several guidelines have been established for the management of tumours associated with VHL syndrome, none of these have specifically focused on pancreatic lesions. Thus, we aim to characterize the types of pancreatic lesions associated with VHL disease and their natural history, to identify particular lesions that necessitate treatment, and to define what forms of treatment should be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=84962118421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962118421&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2016.37

DO - 10.1038/nrclinonc.2016.37

M3 - Article

C2 - 27030075

AN - SCOPUS:84962118421

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -